Delirium in psychiatric inpatients: a case-control study

Patten, Scott B; Patten, S B; Williams, J V; Petcu, R; Oldfield, R
March 2001
Canadian Journal of Psychiatry;Mar2001, Vol. 46 Issue 2, p162
Academic Journal
journal article
Objective: To investigate the clinical and pharmacoepidemiological determinants of delirium in a psychiatric inpatient population.Method: A case-control study design was used. Potential cases and potential controls were identified using hospital discharge data. The clinical record of each subject was reviewed using a validated protocol to confirm case and control status. Subsequently, exposure data were recorded from clinical records.Results: Subjects admitted to hospital with delirium tended to be older, to have pre-existing cognitive deficits, and to have diagnoses of substance use disorders. Subjects who developed delirium after their admission to hospital were older than control subjects, more likely to have a history of cognitive impairment, and were significantly more likely to be treated during the hospitalization with lithium or anticholinergic antiparkinsonian medications. Antipsychotic medication exposures were also associated with delirium, but only at standard or above-standard dosage levels. Antidepressant and sedative-hypnotic medications were not associated with delirium.Conclusions: These findings indicate that using conservative dosages of antipsychotic medications and minimizing the use of anticholinergic medications for parkinsonian symptoms may help to prevent delirium in psychiatric inpatients. Anticonvulsant mood stabilizers may convey less delirium risk than lithium. Antidepressant medications and sedative-hypnotics were not important determinants of delirium in this population.


Related Articles

  • Optimal haloperidol dosage in first-episode psychosis. Zhang-Wong, J; Zipurskcy, RB; Beiser, M; Bean, G; Zipursky, R B // Canadian Journal of Psychiatry;Mar1999, Vol. 44 Issue 2, p164 

    Objective: To determine optimal doses of haloperidol for the treatment of a first episode of psychosis.Method: A 4-week prospective controlled clinical trial with "optimal dose" defined as the dose at which either of the following occurs: 1) significant improvement,...

  • The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial. Duprey, Matthew; Al-Qadheeb, Nada; Roberts, Russel; Skrobik, Yoanna; Schumaker, Greg; Devlin, John; Duprey, Matthew S; Devlin, John W // Intensive Care Medicine;Nov2016, Vol. 42 Issue 11, p1818 

    A letter to the editor is presented in response to the article "The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo controlled trial" in the September 16, 2016 issue.

  • Ketamine use in sedation management in patients receiving extracorporeal membrane oxygenation. Dzierba, Amy; Brodie, Daniel; Bacchetta, Matthew; Muir, Justin; Wasson, Lauren; Colabraro, Michael; Gannon, Whitney; Connolly, Kathleen; Biscotti, Mauer; Rietdijk, Wim; Moitra, Vivek; Bakker, Jan; Dzierba, Amy L // Intensive Care Medicine;Nov2016, Vol. 42 Issue 11, p1822 

    A letter to the editor is presented in response to the article "Ketamine use in sedation management in patients receiving extracorporeal membrane oxygenation" in the September 12, 2016 issue.

  • Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. Beck, Hans-Peter; Wampfler, Rahel; Carter, Nick; Koh, Gavin; Osorio, Lyda; Rueangweerayut, Ronnatrai; Krudsood, Srivcha; Lacerda, Marcus V.; Llanos-Cuentas, Alejandro; Duparc, Stephan; Rubio, Justin P.; Green, Justin A. // Journal of Infectious Diseases;3/1/2016, Vol. 213 Issue 5, p794 

    Unlabelled: Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically...

  • Olanzapine use in the elderly: a retrospective analysis. Solomons, Kevin; Geiger, Odie; Solomons, K; Geiger, O // Canadian Journal of Psychiatry;Mar2000, Vol. 45 Issue 2, p151 

    Objective: To evaluate the efficacy and safety of olanzapine in a hospitalized geriatric population that had previously failed to respond to, or tolerate, numerous trials with other antipsychotic medications. Method: A retrospective chart analysis was conducted on 58...

  • Antipsychotic drugs and obesity: is prolactin involved? Baptista, Trino; Lacruz, Anny; Meza, Teraiza; Contreras, Quilianio; Delgado, Carlos; Mejias, Maria A; Hernàndez, Luis; Baptista, T; Lacruz, A; Meza, T; Contreras, Q; Delgado, C; Mejìas, M A; Hernàndez, L // Canadian Journal of Psychiatry;Nov2001, Vol. 46 Issue 9, p829 

    Objectives: To correlate the anthropometric indexes (Body Mass Index [BMI] and Waist-Hip ratio [WHR]) with the serum prolactin levels in a heterogeneous population of patients treated with typical antipsychotic (AP) drugs.Methods: We evaluated BMI, WHR, and fasting...

  • Treatment intensification and blood glucose control among hospitalized diabetic patients. Matheny, Michael E.; Shubina, Maria; Kimmel, Zebadiah M.; Pendergrass, Merri L.; Turchin, Alexander // JGIM: Journal of General Internal Medicine;Feb2008, Vol. 23 Issue 2, p184 

    Background: Hyperglycemia is common among diabetic inpatients, and has been linked to adverse outcomes. However, antihyperglycemic treatment is seldom intensified in noncritical care patients, and the relationship between intensification frequency and glucose control is poorly...

  • Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Francobandiera, Giorgio; Francobandiera, G // Canadian Journal of Psychiatry;May2001, Vol. 46 Issue 4, p356 

    Objective: This study evaluates the clinical response to olanzapine used in association with selective serotonin reuptake inhibitors (SSRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD). Methods: We describe the cases of 9 patients with...

  • Drug treatment of panic disorder. Reply to comment by Marks and associates. Klerman, Gerald L.; Klerman, G L // British Journal of Psychiatry;Oct92, Vol. 161, p465 

    A response by Gerald L. Klerman to a letter to the editor about his article on the summary report from the Second Phase of the Cross-National Collaborative Panic Study published in the February 1992 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics